Fibroblast growth factor-1 (FGF-1) is a well characterized growth factor among the 22 members of the FGF superfamily in humans. It binds to all the four known FGF receptors and regulates a plethora of functions including cell growth, proliferation, migration, differentiation, and survival in different cell types. FGF-1 is involved in the regulation of diverse physiological processes such as development, angiogenesis, wound healing, adipogenesis, and neurogenesis. Deregulation of FGF-1 signaling is not only implicated in tumorigenesis but also is associated with tumor invasion and metastasis. Given the biomedical significance of FGFs and the fact that individual FGFs have different roles in diverse physiological processes, the analysis of signaling pathways induced by the binding of specific FGFs to their cognate receptors demands more focused efforts. Currently, there are no resources in the public domain that facilitate the analysis of signaling pathways induced by individual FGFs in the FGF/FGFR signaling system. Towards this, we have developed a resource of signaling reactions triggered by FGF-1/FGFR system in various cell types/tissues. The pathway data and the reaction map are made available for download in different community standard data exchange formats through NetPath and NetSlim signaling pathway resources. 1. Introduction Fibroblast growth factor (FGF) superfamily consists of structurally related polypeptides most of which function through its high affinity fibroblast growth factor receptors (FGFRs). In addition to FGFRs, they also bind to heparan sulfate proteoglycans (HPSGs) and their analog, heparin. These interactions influence the stability of FGFs in the extracellular matrix and also regulate their binding and activation of FGFRs [1–9]. In humans, FGFs are encoded by 22 genes, FGF-1-14 and FGF-16-23, and are divided into 7 subfamilies. FGFs 1–10 and 16–23 are FGFR ligands, while FGFs 11–14 are intracellular FGF homologous factors which act in a receptor-independent fashion [10]. Knock-out mice of different FGFs exhibit diverse developmental and physiological disorders [11]. For instance, FGF-9 is involved in the development of lung and testes [12, 13], FGF-3 is critical for inner ear development [14], and FGF-18 is important in bone and lung development [15–17]. Moreover, knock-out of FGFs 4, 8, 9, 10, 15, 18, or 23 was found to be lethal in mice [18]. FGFs are also involved in wound healing, tissue repair [19, 20], and angiogenesis [21]. Facilitating cell proliferation, migration, and differentiation [16, 22–26], FGFs are implicated
References
[1]
N. J. Harmer, “Insights into the role of heparan sulphate in fibroblast growth factor signalling,” Biochemical Society Transactions, vol. 34, no. 3, pp. 442–445, 2006.
[2]
O. A. Ibrahimi, F. Zhang, S. C. L. Hrstka, M. Mohammadi, and R. J. Linhardt, “Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly,” Biochemistry, vol. 43, no. 16, pp. 4724–4730, 2004.
[3]
D. M. Ornitz, A. B. Herr, M. Nilsson, J. Westman, C.-M. Svahn, and G. Waksman, “FGF binding and FGF receptor activation by synthetic heparan-derived di- and trisaccharides,” Science, vol. 268, no. 5209, pp. 432–436, 1995.
[4]
M. W. Pantoliano, “Multivalent ligand-receptor binding interactions in the fibroblast growth factor system produce a cooperative growth factor and heparin mechanism for receptor dimerization,” Biochemistry, vol. 33, no. 34, pp. 10229–10248, 1994.
[5]
D. M. Ornitz and P. Leder, “Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3,” The Journal of Biological Chemistry, vol. 267, no. 23, pp. 16305–16311, 1992.
[6]
D. M. Ornitz, A. Yayon, J. G. Flanagan, C. M. Svahn, E. Levi, and P. Leder, “Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells,” Molecular and Cellular Biology, vol. 12, no. 1, pp. 240–247, 1992.
[7]
A. Yayon, M. Klagsbrun, J. D. Esko, P. Leder, and D. M. Ornitz, “Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor,” Cell, vol. 64, no. 4, pp. 841–848, 1991.
[8]
O. Saksela, D. Moscatelli, A. Sommer, and D. B. Rifkin, “Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation,” Journal of Cell Biology, vol. 107, no. 2, pp. 743–751, 1988.
[9]
D. Gospodarowicz and J. Cheng, “Heparin protects basic and acidic FGF from inactivation,” Journal of Cellular Physiology, vol. 128, no. 3, pp. 475–484, 1986.
[10]
N. Itoh and D. M. Ornitz, “Evolution of the Fgf and Fgfr gene families,” Trends in Genetics, vol. 20, no. 11, pp. 563–569, 2004.
[11]
A. Beenken and M. Mohammadi, “The FGF family: biology, pathophysiology and therapy,” Nature Reviews Drug Discovery, vol. 8, no. 3, pp. 235–253, 2009.
[12]
J. S. Colvin, A. C. white, S. J. Pratt, and D. M. Ornitz, “Lung hypoplasia and neonatal death in Fgf9-null mice identify this gene as an essential regulator of lung mesenchyme,” Development, vol. 128, no. 11, pp. 2095–2106, 2001.
[13]
J. S. Colvin, R. P. Green, J. Schmahl, B. Capel, and D. M. Ornitz, “Male-to-female sex reversal in mice lacking fibroblast growth factor 9,” Cell, vol. 104, no. 6, pp. 875–889, 2001.
[14]
M. Tekin, B. ？. Hi？mi, S. Fitoz et al., “Homozygous mutations in fibroblast growth factor 3 are associated with a new form of syndromic deafness characterized by inner ear agenesis, microtia, and microdontia,” American Journal of Human Genetics, vol. 80, no. 2, pp. 338–344, 2007.
[15]
H. Usui, M. Shibayama, N. Ohbayashi, M. Konishi, S. Takada, and N. Itoh, “Fgf18 is required for embryonic lung alveolar development,” Biochemical and Biophysical Research Communications, vol. 322, no. 3, pp. 887–892, 2004.
[16]
N. Ohbayashi, M. Shibayama, Y. Kurotaki et al., “FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis,” Genes and Development, vol. 16, no. 7, pp. 870–879, 2002.
[17]
Z. Liu, J. Xu, J. S. Colvin, and D. M. Ornitz, “Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18,” Genes and Development, vol. 16, no. 7, pp. 859–869, 2002.
[18]
N. Itoh and D. M. Ornitz, “Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease,” Journal of Biochemistry, vol. 149, no. 2, pp. 121–130, 2011.
[19]
S. Werner, K. G. Peters, M. T. Longaker, F. Fuller-Pace, M. J. Banda, and L. T. Williams, “Large induction of keratinocyte growth factor expression in the dermis during wound healing,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 15, pp. 6896–6900, 1992.
[20]
P. Rieck, M. Assouline, M. Savoldelli et al., “Recombinant human basic fibroblast growth factor (Rh-bFGF) in three different wound models in rabbits: corneal wound healing effect and pharmacology,” Experimental Eye Research, vol. 54, no. 6, pp. 987–998, 1992.
[21]
J. Slavin, “Fibroblast growth factors: at the heart of angiogenesis,” Cell Biology International, vol. 19, no. 5, pp. 431–444, 1995.
[22]
W. A. Hossain and D. K. Morest, “Fibroblast growth factors (FGF-1, FGF-2) promote migration and neurite growth of mouse cochlear ganglion cells in vitro: immunohistochemistry and antibody perturbation,” Journal of Neuroscience Research, vol. 62, no. 1, pp. 40–55, 2000.
[23]
S. Tanaka, T. Kunath, A.-K. Hadjantonakis, A. Nagy, and J. Rossant, “Promotion to trophoblast stem cell proliferation by FGF4,” Science, vol. 282, no. 5396, pp. 2072–2075, 1998.
[24]
S. E. Webb, K. K. Lee, M. K. Tang, et al., “Fibroblast growth factors 2 and 4 stimulate migration of mouse embryonic limb myogenic cells,” Developmental Dynamics, vol. 209, no. 2, pp. 206–216, 1997.
[25]
S. Werner, W. Weinberg, X. Liao et al., “Targeted expression of a dominant-negative FGF receptor mutant in the epidermis of transgenic mice reveals a role of FGF in keratinocyte organization and differentiation,” EMBO Journal, vol. 12, no. 7, pp. 2635–2643, 1993.
[26]
M. Murphy, J. Drago, and P. F. Bartlett, “Fibroblast growth factor stimulates the proliferation and differentiation of neural precursor cells in vitro,” Journal of Neuroscience Research, vol. 25, no. 4, pp. 463–475, 1990.
[27]
N. Turner and R. Grose, “Fibroblast growth factor signalling: from development to cancer,” Nature Reviews Cancer, vol. 10, no. 2, pp. 116–129, 2010.
[28]
D. Gospodarowicz, “Localisation of a fibroblast growth factor and its effect along and with hydrocortisone on 3T3 cell growth,” Nature, vol. 249, no. 5453, pp. 123–127, 1974.
[29]
H. A. Armelin, “Pituitary extracts and steroid hormones in the control of 3T3 cell growth,” Proceedings of the National Academy of Sciences of the United States of America, vol. 70, no. 9, pp. 2702–2706, 1973.
[30]
C. M. Carreira, M. Landriscina, S. Bellum, I. Prudovsky, and T. Maciag, “The comparative release of FGF1 by hypoxia and temperature stress,” Growth Factors, vol. 18, no. 4, pp. 277–285, 2001.
[31]
A. Jackson, S. Friedman, X. Zhan, K. A. Engleka, R. Forough, and T. Maciag, “Heat shock induces the release of fibroblast growth factor 1 from NIH 3T3 cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 22, pp. 10691–10695, 1992.
[32]
J. T. Shin, S. R. Opalenik, J. N. Wehby et al., “Serum-starvation induces the extracellular appearance of FGF-1,” Biochimica et Biophysica Acta, Molecular Cell Research, vol. 1312, no. 1, pp. 27–38, 1996.
[33]
N. M. Ananyeva, A. V. Tjurmin, J. A. Berliner, et al., “Oxidized LDL mediates the release of fibroblast growth factor-1,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 3, pp. 445–453, 1997.
[34]
S. K. Mohan, S. G. Rani, S. M. Kumar, and C. Yu, “S100A13-C2A binary complex structure-a key component in the acidic fibroblast growth factor for the non-classical pathway,” Biochemical and Biophysical Research Communications, vol. 380, no. 3, pp. 514–519, 2009.
[35]
M. Landriscina, C. Bagalá, A. Mandinova et al., “Copper induces the assembly of a multiprotein aggregate implicated in the release of fibroblast growth factor 1 in response to stress,” The Journal of Biological Chemistry, vol. 276, no. 27, pp. 25549–25557, 2001.
[36]
C. M. Carreira, T. M. LaVallee, F. Tarantini et al., “S100A13 is involved in the regulation of fibroblast growth factor-1 and p40 synaptotagmin-1 release in vitro,” The Journal of Biological Chemistry, vol. 273, no. 35, pp. 22224–22231, 1998.
[37]
F. Tarantini, T. Lavallee, A. Jackson et al., “The extravesicular domain of synaptotagmin-1 is released with the latent fibroblast growth factor-1 homodimer in response to heat shock,” The Journal of Biological Chemistry, vol. 273, no. 35, pp. 22209–22216, 1998.
[38]
S. Uriel, E. M. Brey, and H. P. Greisler, “Sustained low levels of fibroblast growth factor-1 promote persistent microvascular network formation,” American Journal of Surgery, vol. 192, no. 5, pp. 604–609, 2006.
[39]
A. Iwakura, M. Fujita, M. Ikemoto et al., “Myocardial ischemia enhances the expression of acidic fibroblast growth factor in human pericardial fluid,” Heart and Vessels, vol. 15, no. 3, pp. 112–116, 2000.
[40]
P. Cuevas, D. Reimers, F. Carceller et al., “Fibroblast growth factor-1 prevents myocardial apoptosis triggered by ischemia reperfusion injury,” European Journal of Medical Research, vol. 2, no. 11, pp. 465–468, 1997.
[41]
J.-C. Wu, W.-C. Huang, Y.-A. Tsai, Y.-C. Chen, and H. Cheng, “Nerve repair using acidic fibroblast growth factor in human cervical spinal cord injury: a preliminary Phase I clinical study,” Journal of Neurosurgery: Spine, vol. 8, no. 3, pp. 208–214, 2008.
[42]
X. Xia, J. P. Babcock, S. I. Blaber, et al., “Pharmacokinetic properties of 2nd-generation fibroblast growth factor-1 mutants for therapeutic application,” PLoS ONE, vol. 7, no. 11, Article ID e48210, 2012.
[43]
J. Belch, W. R. Hiatt, I. Baumgartner et al., “Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia,” The Lancet, vol. 377, no. 9781, pp. 1929–1937, 2011.
[44]
A. J. Comerota, R. C. Throm, K. A. Miller et al., “Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial,” Journal of Vascular Surgery, vol. 35, no. 5, pp. 930–936, 2002.
[45]
B. Birrer, “Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas,” Journal of Clinical Oncology, vol. 25, no. 21, p. 3184, 2007.
[46]
B. Kwabi-Addo, M. Ozen, and M. Ittmann, “The role of fibroblast growth factors and their receptors in prostate cancer,” Endocrine-Related Cancer, vol. 11, no. 4, pp. 709–724, 2004.
[47]
V. P. Eswarakumar, I. Lax, and J. Schlessinger, “Cellular signaling by fibroblast growth factor receptors,” Cytokine and Growth Factor Reviews, vol. 16, no. 2, pp. 139–149, 2005.
[48]
D. M. Ornitz and N. Itoh, “Fibroblast growth factors,” Genome Biology, vol. 2, no. 3, article 3005, 2001.
[49]
M. Bhattacharjee, R. Raju, A. Radhakrishnan, et al., “A bioinformatics resource for TWEAK-Fn14 signaling pathway,” Journal of Signal Transduction, vol. 2012, Article ID 376470, 10 pages, 2012.
[50]
D. Telikicherla, A. Ambekar, S. Palapetta et al., “A comprehensive curated resource for follicle stimulating hormone signaling,” BMC Research Notes, vol. 4, article 408, 2011.
[51]
K. Kandasamy, S. Sujatha Mohan, R. Raju et al., “NetPath: A public resource of curated signal transduction pathways,” Genome Biology, vol. 11, no. 1, article r3, 2010.
[52]
R. Raju, V. Nanjappa, L. Balakrishnan et al., “NetSlim: high-confidence curated signaling maps,” The Journal of Biological Databases and Curation, vol. 2011, p. bar032, 2011.
[53]
M. Manuvakhova, J. V. Thottassery, S. Hays et al., “Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells,” Oncogene, vol. 25, no. 44, pp. 6003–6014, 2006.
[54]
S. H. Ong, Y. R. Hadari, N. Gotoh, G. R. Guy, J. Schlessinger, and I. Lax, “Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 11, pp. 6074–6079, 2001.
[55]
Y. R. Hadari, H. Kouhara, I. Lax, and J. Schlessinger, “Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation,” Molecular and Cellular Biology, vol. 18, no. 7, pp. 3966–3973, 1998.
[56]
H. Kouhara, Y. R. Hadari, T. Spivak-Kroizman et al., “A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway,” Cell, vol. 89, no. 5, pp. 693–702, 1997.
[57]
M. Kanai, M. G？ke, S. Tsunekawa, and D. K. Podolsky, “Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kDa phosphoprotein,” The Journal of Biological Chemistry, vol. 272, no. 10, pp. 6621–6628, 1997.
[58]
Y. R. Hadari, H. Kouhara, I. Lax, and J. Schlessinger, “Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation,” Molecular and Cellular Biology, vol. 18, no. 7, pp. 3966–3973, 1998.
[59]
W.-F. Lin, C.-J. Chen, Y.-J. Chang, S.-L. Chen, I.-M. Chiu, and L. Chen, “SH2B1β enhances fibroblast growth factor 1 (FGF1)-induced neurite outgrowth through MEK-ERK1/2-STAT3-Egr1 pathway,” Cellular Signalling, vol. 21, no. 7, pp. 1060–1072, 2009.
[60]
M. Mohammadi, I. Dikic, A. Sorokin, W. H. Burgess, M. Jaye, and J. Schlessinger, “Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction,” Molecular and Cellular Biology, vol. 16, no. 3, pp. 977–989, 1996.
[61]
A. Willems-Widyastuti, B. M. Vanaudenaerde, R. Vos et al., “Azithromycin attenuates fibroblast growth factors induced vascular endothelial growth factor Via p38MAPK signaling in human airway smooth muscle cells,” Cell Biochemistry and Biophysics, vol. 67, no. 2, pp. 331–339, 2013.
[62]
T. Nishida, J.-I. Ito, Y. Nagayasu, and S. Yokoyama, “FGF-1-induced reactions for biogenesis of apoE-HDL are mediated by Src in rat astrocytes,” Journal of Biochemistry, vol. 146, no. 6, pp. 881–886, 2009.
[63]
C. W. Chen, C. S. Liu, I. M. Chiu, et al., “The signals of FGFs on the neurogenesis of embryonic stem cells,” Journal of Biomedical Science, vol. 17, p. 33, 2010.
[64]
G. Lungu, L. Covaleda, O. Mendes, H. Martini-Stoica, and G. Stoica, “FGF-1-induced matrix metalloproteinase-9 expression in breast cancer cells is mediated by increased activities of NF-kappa;B and activating protein-1,” Molecular Carcinogenesis, vol. 47, no. 6, pp. 424–435, 2008.
[65]
F. S. Newell, H. Su, H. Tornqvist, J. P. Whitehead, J. B. Prins, and L. J. Hutley, “Characterization of the transcriptional and functional effects of fibroblast growth factor-1 on human preadipocyte differentiation,” The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, vol. 20, no. 14, pp. 2615–2617, 2006.
[66]
D. R. Newman, C.-M. Li, R. Simmons, J. Khosla, and P. L. Sannes, “Heparin affects signaling pathways stimulated by fibroblast growth factor-1 and -2 in type II cells,” American Journal of Physiology, Lung Cellular and Molecular Physiology, vol. 287, no. 1, pp. L191–L200, 2004.
[67]
A. Buehlera, A. Martirea, C. Strohma, et al., “Angiogenesis-independent cardioprotection in FGF-1 transgenic mice,” Cardiovascular Research, vol. 55, no. 4, pp. 768–777, 2002.
[68]
C. A. Castaneda, H. Cortes-Funes, H. L. Gomez, and E. M. Ciruelos, “The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer,” Cancer Metastasis Reviews, vol. 29, no. 4, pp. 751–759, 2010.
[69]
J.-I. Ito, Y. Nagayasu, K. Okumura-Noji et al., “Mechanism for FGF-1 to regulate biogenesis of apoE-HDL in astrocytes,” Journal of Lipid Research, vol. 48, no. 9, pp. 2020–2027, 2007.
[70]
R. Forough, B. Weylie, C. Patel, S. Ambrus, U. S. Singh, and J. Zhu, “Role of AKT/PKB signaling in fibroblast growth factor-1 (FGF-1)-induced angiogenesis in the chicken chorioallantoic membrane (CAM),” Journal of Cellular Biochemistry, vol. 94, no. 1, pp. 109–116, 2005.
[71]
J. Wang, T. Ito, N. Udaka, K. Okudela, T. Yazawa, and H. Kitamura, “PI3K-AKT pathway mediates growth and survival signals during development of fetal mouse lung,” Tissue and Cell, vol. 37, no. 1, pp. 25–35, 2005.
[72]
W.-F. Lin, C.-J. Chen, Y.-J. Chang, S.-L. Chen, I.-M. Chiu, and L. Chen, “SH2B1β enhances fibroblast growth factor 1 (FGF1)-induced neurite outgrowth through MEK-ERK1/2-STAT3-Egr1 pathway,” Cellular Signalling, vol. 21, no. 7, pp. 1060–1072, 2009.
[73]
M. A. Hossain, J. C. Russell, R. Gomes, and J. Laterra, “Neuroprotection by scatter factor/hepatocyte growth factor and FGF-1 in cerebellar granule neurons is phosphatidylinositol 3-kinase/Akt-dependent and MAPK/CREB-independent,” Journal of Neurochemistry, vol. 81, no. 2, pp. 365–378, 2002.
[74]
P. Li, S. Oparil, W. Feng, and Y.-F. Chen, “Hypoxia-responsive growth factors upregulate periostin and osteopontin expression via distinct signaling pathways in rat pulmonary arterial smooth muscle cells,” Journal of Applied Physiology, vol. 97, no. 4, pp. 1550–1558, 2004.
[75]
A. Raucci, E. Laplantine, A. Mansukhani, and C. Basilico, “Activation of the ERK1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes,” The Journal of Biological Chemistry, vol. 279, no. 3, pp. 1747–1756, 2004.
[76]
J. Jiao, J. S. Greendorfer, P. Zhang, K. R. Zinn, C. A. Diglio, and J. A. Thompson, “Alternatively spliced FGFR-1 isoform signaling differentially modulates endothelial cell responses to peroxynitrite,” Archives of Biochemistry and Biophysics, vol. 410, no. 2, pp. 187–200, 2003.
[77]
P. B. Mehta, C. N. Robson, D. E. Neal, and H. Y. Leung, “Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells,” Oncogene, vol. 20, no. 38, pp. 5359–5365, 2001.
[78]
Y. J. Chang, K. W. Chen, C. J. Chen, et al., “SH2B1β interacts with STAT3 and enhances fibroblast growth factor 1-induced gene expression during neuronal differentiation,” Molecular and Cellular Biology, vol. 34, no. 6, pp. 1003–1019, 2014.
[79]
A. A. Dudka, S. M. M. Sweet, and J. K. Heath, “Signal transducers and activators of transcription-3 binding to the fibroblast growth factor receptor is activated by receptor amplification,” Cancer Research, vol. 70, no. 8, pp. 3391–3401, 2010.
[80]
W.-F. Lin, C.-J. Chen, Y.-J. Chang, S.-L. Chen, I.-M. Chiu, and L. Chen, “SH2B1β enhances fibroblast growth factor 1 (FGF1)-induced neurite outgrowth through MEK-ERK1/2-STAT3-Egr1 pathway,” Cellular Signalling, vol. 21, no. 7, pp. 1060–1072, 2009.
[81]
G. Lungu, L. Covaleda, O. Mendes, H. Martini-Stoica, and G. Stoica, “FGF-1-induced matrix metalloproteinase-9 expression in breast cancer cells is mediated by increased activities of NF-kappa;B and activating protein-1,” Molecular Carcinogenesis, vol. 47, no. 6, pp. 424–435, 2008.
[82]
X. Zhu, J. Sasse, D. McAllister, et al., “Evidence that fibroblast growth factors 1 and 4 participate in regulation of cardiogenesis,” Developmental Dynamics, vol. 207, no. 4, pp. 429–438, 1996.
[83]
X. Qu, K. Hertzler, Y. Pan, K. Grobe, M. L. Robinson, and X. Zhang, “Genetic epistasis between heparan sulfate and FGF-Ras signaling controls lens development,” Developmental Biology, vol. 355, no. 1, pp. 12–20, 2011.
[84]
A. E. Serls, S. Doherty, P. Parvatiyar, J. M. Wells, and G. H. Deutsch, “Different thresholds of fibroblast growth factors pattern the ventral foregut into liver and lung,” Development, vol. 132, no. 1, pp. 35–47, 2005.
[85]
D. Lebeche, S. Malpel, and W. V. Cardoso, “Fibroblast growth factor interactions in the developing lung,” Mechanisms of Development, vol. 86, no. 1-2, pp. 125–136, 1999.
[86]
J. Jung, M. Zheng, M. Goldfarb, and K. S. Zaret, “Initiation of mammalian liver development from endoderm by fibroblast growth factors,” Science, vol. 284, no. 5422, pp. 1998–2003, 1999.
[87]
X. Luo, L. J. Hutley, J. A. Webster et al., “Identification of BMP and activin membrane-bound inhibitor (BAMBI) as a potent negative regulator of adipogenesis and modulator of autocrine/paracrine adipogenic factors,” Diabetes, vol. 61, no. 1, pp. 124–136, 2012.
[88]
L. Hutley, W. Shurety, F. Newell et al., “Fibroblast growth factor 1: a key regulator of human adipogenesis,” Diabetes, vol. 53, no. 12, pp. 3097–3106, 2004.
[89]
T. Tran, V. Kolupaeva, and C. Basilico, “FGF inhibits the activity of the cyclin B1/CDK1 kinase to induce a transient G2 arrest in RCS chondrocytes,” Cell Cycle, vol. 9, no. 21, pp. 4379–4386, 2010.
[90]
V. Kolupaeva, E. Laplantine, and C. Basilico, “PP2A-mediated dephosphorylation of p107 plays a critical role in chondrocyte cell cycle arrest by FGF,” PLoS ONE, vol. 3, no. 10, Article ID e3447, 2008.
[91]
R. Priore, L. Dailey, and C. Basilico, “Downregulation of Akt activity contributes to the growth arrest induced by FGF in chondrocytes,” Journal of Cellular Physiology, vol. 207, no. 3, pp. 800–808, 2006.
[92]
L. Dailey, E. Laplantine, R. Priore, and C. Basilico, “A network of transcriptional and signaling events is activated by FGF to induce chondrocyte growth arrest and differentiation,” Journal of Cell Biology, vol. 161, no. 6, pp. 1053–1066, 2003.
[93]
P. Zhang, J. S. Greendorfer, J. Jiao, S. C. Kelpke, and J. A. Thompson, “Alternatively spliced FGFR-1 isoforms differentially modulate endothelial cell activation of c-YES,” Archives of Biochemistry and Biophysics, vol. 450, no. 1, pp. 50–62, 2006.
[94]
B. Fernandez, A. Buehler, S. Wolfram et al., “Transgenic myocardial overexpression of fibroblast growth factor-1 increases coronary artery density and branching,” Circulation Research, vol. 87, no. 3, pp. 207–213, 2000.
[95]
B. Schumacher, P. Peecher, B. U. Von Specht, and T. Stegmann, “Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease,” Circulation, vol. 97, no. 7, pp. 645–650, 1998.
[96]
J.-I. Ito, Y. Nagayasu, R. Lu, A. Kheirollah, M. Hayashi, and S. Yokoyama, “Astrocytes produce and secrete FGF-1, which promotes the production of apoE-HDL in a manner of autocrine action,” Journal of Lipid Research, vol. 46, no. 4, pp. 679–686, 2005.
[97]
L. Sun, L. Xu, H. Chang et al., “Transfection with aFGF cDNA improves wound healing,” Journal of Investigative Dermatology, vol. 108, no. 3, pp. 313–318, 1997.
[98]
U. Pirvola, Y. Cao, C. Oellig, Z. Suoqiang, R. F. Pettersson, and J. Ylikoski, “The site of action of neuronal acidic fibroblast growth factor is the organ of corti of the rat cochlea,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 20, pp. 9269–9273, 1995.
[99]
M. Palmen, M. J. A. P. Daemen, L. J. De Windt et al., “Fibroblast growth factor-1 improves cardiac functional recovery and enhances cell survival after ischemia and reperfusion: a fibroblast growth factor receptor, protein kinase C, and tyrosine kinase-dependent mechanism,” Journal of the American College of Cardiology, vol. 44, no. 5, pp. 1113–1123, 2004.
[100]
A. Buehler, A. Martire, C. Strohm et al., “Angiogenesis-independent cardioprotection in FGF-1 transgenic mice,” Cardiovascular Research, vol. 55, no. 4, pp. 768–777, 2002.
[101]
P. Htun, W. D. Ito, I. E. Hoefer, J. Schaper, and W. Schaper, “Intramyocardial infusion of FGF-1 mimics ischemic preconditioning in pig myocardium,” Journal of Molecular and Cellular Cardiology, vol. 30, no. 4, pp. 867–877, 1998.
[102]
M. Hashimoto, Y. Sagara, D. Langford et al., “Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3β pathway. Implications for neuroprotection,” The Journal of Biological Chemistry, vol. 277, no. 36, pp. 32985–32991, 2002.
[103]
J. Taeger, C. Moser, C. Hellerbrand et al., “Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer,” Molecular Cancer Therapeutics, vol. 10, no. 11, pp. 2157–2167, 2011.
[104]
E. M. Haugsten, M. Zakrzewska, A. Brech et al., “Clathrin- and dynamin-independent endocytosis of fgfr3—implications for signalling,” PLoS ONE, vol. 6, no. 7, Article ID e21708, 2011.
[105]
C. Bonneton, J. B. Sibarita, and J. P. Thiery, “Relationship between cell migration and cell cycle during the initiation of epithelial to fibroblastoid transition,” Cell Motility and the Cytoskeleton, vol. 43, no. 4, pp. 288–295, 1999.
[106]
Z. Liu, Y. E. Hartman, J. M. Warram et al., “Fibroblast growth factor receptor mediates fibroblast-dependent growth in EMMPRIN-depleted head and neck cancer tumor cells,” Molecular Cancer Research, vol. 9, no. 8, pp. 1008–1017, 2011.
[107]
N. R. Estes II, J. V. Thottassery, L. Westbrook, and F. G. Kern, “MEK ablation in MCF-7 cells blocks DNA synthesis induced by serum, but not by estradiol or growth factors,” International Journal of Oncology, vol. 29, no. 6, pp. 1573–1580, 2006.
[108]
O. Klingenberg, A. Wi？d？ocha, A. Rapak, R. Mu？oz, P. ？. Falnes, and S. Olsnes, “Inability of the acidic fibroblast growth factor mutant K132E to stimulate DNA synthesis after translocation into cells,” The Journal of Biological Chemistry, vol. 273, no. 18, pp. 11164–11172, 1998.
[109]
J.-M. Rodier, A. M. Valles, M. Denoyelle, J. P. Thiery, and B. Boyer, “pp60(c-src) Is a positive regulator of growth factor-induced cell scattering in a rat bladder carcinoma cell line,” Journal of Cell Biology, vol. 131, no. 3, pp. 761–773, 1995.
[110]
A. M. Valles, B. Boyer, J. Badet, G. C. Tucker, D. Barritault, and J. P. Thiery, “Acidic fibroblast growth factor is a modulator of epithelial plasticity in a rat bladder carcinoma cell line,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 3, pp. 1124–1128, 1990.
[111]
J. Jouanneau, J. Plouet, G. Moens, and J. P. Thiery, “FGF-2 and FGF-1 expressed in rat bladder carcinoma cells have similar angiogenic potential but different tumorigenic properties in vivo,” Oncogene, vol. 14, no. 6, pp. 671–676, 1997.
[112]
J. Jouanneau, J. Gavrilovic, D. Caruelle et al., “Secreted or nonsecreted forms of acidic fibroblast growth factor produced by transfected epithelial cells influence cell morphology, motility, and invasive potential,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 7, pp. 2893–2897, 1991.
[113]
P. Shannon, A. Markiel, O. Ozier et al., “Cytoscape: a software environment for integrated models of biomolecular interaction networks,” Genome Research, vol. 13, no. 11, pp. 2498–2504, 2003.
[114]
O. Babur, U. Dogrusoz, E. Demir, and C. Sander, “ChiBE: interactive visualization and manipulation of BioPAX pathway models,” Bioinformatics, vol. 26, no. 3, pp. 429–431, 2010.
[115]
A. Dilek, M. E. Belviranli, and U. Dogrusoz, “VISIBIOweb: visualization and layout services for BioPAX pathway models,” Nucleic Acids Research, vol. 38, no. 2, Article ID gkq352, pp. W150–W154, 2010.
[116]
M. P. van Iersel, T. Kelder, A. R. Pico et al., “Presenting and exploring biological pathways with PathVisio,” BMC Bioinformatics, vol. 9, article 399, 2008.
[117]
T. S. K. Prasad, R. Goel, K. Kandasamy et al., “Human protein reference database—2009 update,” Nucleic Acids Research, vol. 37, no. 1, pp. D767–D772, 2009.
